Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
1 No-Brainer Stock to Buy and Hold for 10 Years
08:30am, Saturday, 11'th Nov 2023
CRISPR is a leader in the young but promising gene-editing niche. The biotech is getting closer to earning its first major approval.
3 Biotech Stocks That Are Betting on the Future of Gene Editing
03:37pm, Thursday, 09'th Nov 2023
The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.
3 Biotech Stocks With the Strongest Clinical Pipelines
05:24pm, Wednesday, 08'th Nov 2023
Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the int
Why CRISPR Therapeutics Stock Could Be About to Take Off
10:07am, Wednesday, 08'th Nov 2023
CRISPR Therapeutics could soon have an approved product in its portfolio. The stock's modest valuation suggests there could be significant upside.
Why CRISPR Therapeutics Stock Crushed the Market Today
06:52pm, Tuesday, 07'th Nov 2023
There's nothing like a convincing quarterly earnings beat. The gene-editing specialist's net loss was far narrower than expected.
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
08:30am, Sunday, 05'th Nov 2023
Biotech stocks have been under extreme pressure over the prior 24 months. This industry-wide move lower may have created a handful of once-in-a-lifetime opportunities for investors.
Why CRISPR Therapeutics Stock Charged Northward This Week
09:56am, Friday, 03'rd Nov 2023
Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week after a panel of experts potentially set the stage f
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
08:05am, Friday, 03'rd Nov 2023
Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.
CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors
11:27am, Thursday, 02'nd Nov 2023
CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, s
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
05:30am, Thursday, 02'nd Nov 2023
CRISPR Therapeutics' first gene-editing candidate is moving closer to the finish line. An FDA advisory meeting this week set a positive tone ahead of a big regulatory decision.
CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?
04:31am, Thursday, 02'nd Nov 2023
CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
Why Are Stocks Up Today?
10:47am, Wednesday, 01'st Nov 2023
Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Committee (FOMC) meeting taking place today will result
CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
10:11am, Wednesday, 01'st Nov 2023
After being halted yesterday during the deliberations of a Food and Drug Administration (FDA) advisory committee, CRISPR Therapeutics (NASDAQ: CRSP ) stock is rallying 5% today in early trading. That
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients
05:14pm, Tuesday, 31'st Oct 2023
The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.
FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia
03:43pm, Tuesday, 31'st Oct 2023
Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.
